Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Wave Life Sciences reports transformative 2022 with promising clinical advancements

Wave Life Sciences showcased strong clinical progress and financial discipline in Q4 2022.
The collaboration with GSK and advancements in RNA editing and RNAi technologies position Wave for future success.
Despite challenges in increased expenses, Wave's focus on innovative therapies and strategic partnerships bode well for their future.

Wave Life Sciences reports Q1 progress, poised for RNA innovation

Wave Life Sciences showcased strong financial performance, significant program advancements, and a leadership position in RNA editing technology during Q1 2023.
The company's strategic shift, collaboration with GSK, and focus on additional endpoints beyond traditional measures highlight their commitment to innovation and patient outcomes.
While facing challenges in study designs and editing efficiency assessments, Wave's opportunities lie in differentiation, partnerships, and further advancements in precision medicine.

Wave Life Sciences advances RNA editing technology and secures key collaborations

Wave Life Sciences showcased strong progress in RNA editing and clinical programs, bolstered by collaborations and financial stability.
While facing challenges in off-target effects and patient selection, Wave aims to demonstrate leadership in protein restoration through RNA editing.
Anticipated milestones from GSK, advancements in AIMer technology, and upcoming trial data offer promising opportunities for Wave's growth.

Wave Life Sciences reports strong Q3 earnings and advances RNA pipeline

Wave Life Sciences demonstrated financial strength with positive net income and a healthy cash position.
The company's focus on RNA medicine pipeline advancement and collaborations with GSK show promise for future growth.
Challenges lie in addressing questions on program development, treatment functionality, and ensuring treatment efficacy and patient compliance.

Wave Life Sciences reports successful 2023, eyes growth in RNA editing and obesity programs

Wave Life Sciences had a successful year in 2023, with promising advancements in key programs and a stable financial position.
The company faces challenges in managing expenses and meeting high expectations for upcoming clinical data readouts.
However, Wave's strengths lie in its innovative RNA editing technology, diversified pipeline, and collaborations for revenue generation.
Opportunities abound in market differentiation, revenue growth, and addressing unmet medical needs through their unique programs.

Wave Life Sciences reports Q1 loss but shows promise in therapies

Wave Life Sciences is making strides in advancing their therapeutic portfolio with promising clinical trial progress and positive preclinical results.
While facing challenges in program validation and expansion, the company's strong R&D efforts and financial stability position them well for future growth.
With upcoming milestones and a focus on innovative therapies, Wave has opportunities to establish itself as a key player in the biopharmaceutical industry.

Wave Life Sciences reports breakthroughs in RNA editing and clinical progress

Wave Life Sciences showcased a successful quarter with advancements in RNA editing and positive clinical trial outcomes, positioning the company for future growth.
While facing financial challenges, the company's strong cash position and promising pipeline present opportunities for sustained innovation and market expansion.
Navigating regulatory pathways for accelerated approvals and leveraging breakthrough technologies underscore Wave's potential for long-term success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.62 per share a year ago.

Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates

Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs

Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, May 3, 2023, to review the company's first quarter 2023 financial results and provide business updates.

Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA formats

Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.

Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days

Wave Life Sciences Ltd (NASDAQ:WVE ) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET Company Participants Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Mike Linden - Mizuho Joon Lee - Truist Securities Julian Pino - Stifel Operator Good morning, and welcome to the Wave Life Sciences Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Wave Life Sciences Ltd (WVE) Q4 2022 Earnings Call Transcript

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic

Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company's fourth quarter and full year 2022 financial results and provide a business update.

Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know

Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.

Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference

Wave Life Sciences caught a strong bid throughout the bulk of 2022, with the trend extending into the new year. Its novel hypothesis in Huntington's disease has piqued our interest most.

Wave Life Sciences: Huntington's Hypotheses, GSK Collaboration Catalysts To Move The Needle

Boeing

Caterpillar

Celsius Holdings

Clearfield

Vita Coco

Chevron

DocGo

Enphase Energy

JPMorgan Chase & Co

McDonald's

Merck

Noble Corp PLC

Northern Oil and Gas

Nuvalent

Permian Basin Royalty Trust

Pinduoduo Inc - ADR

Tidewater

TG Therapeutics

Mammoth Energy Services

Visa

Vipshop Hlds

Viridian Therapeutics

Verizon

Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.

MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge

All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy

AVEO Pharma

Cabaletta Bio

Verona Pharma

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

4 Drug Stocks That More Than Doubled This Year

Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy

Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets

Wave Life Sciences (WVE) Up 26% on Collaboration With GSK

GlaxoSmithKline

Shares of Wave Life Sciences Ltd. WVE, -7.20% jumped about 17% in premarket trading on Tuesday after the company announced a four-year strategic collaboration with GlaxoSmithKline GSK, -0.72% to develop oligonucleotide therapeutics.

Wave, GSK enter strategic collaboration

Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Salim Syed - Mizuho Joon Lee - Truist Securities Mani Foroohar - SVB Securities Operator Good morning, and welcome to the Wave Life Sciences' Third Quarter 2022 Financial Results Conference Call.

Wave Life Sciences Ltd. (WVE) Q3 2022 Earnings Call Transcript

Wave Life Sciences (WVE) delivered earnings and revenue surprises of 12.50% and 94.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT protein in CSF

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on Wednesday, November 16, 2022, at 3:35 p.m. ET.

Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference

Clean Energy Fuels

ConocoPhillips

Dow Inc

Goldman Sachs

Intel

Cheniere Energy

MAG Silver

MGP Ingredients

Brigham Minerals

RingCentral

TravelCenters of America

Travelers

Encore Wire

Two new Breakout Stocks for Week 45 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +109.9% YTD. This week one stock gained 10% in less than a week with EPM +10.6% and GWH +7.6% while ENVX missed Q3 earnings for a terrible -41.7% decline.

MDA Breakout Stocks Week 45 - November 2022: Short-Term Picks To Give You An Edge

News for Wave Life Sciences Stock (WVE)